News

TCB wins High Growth Company of the Year

TCB has won the High Growth Company of the Year award at Scotland's Life Science Awards supported by Scottish Enterprise.

16 May 2018

8 May 2018

TC BioPharm broadens CAR-T drug pipeline

TC BioPharm will collaborate with Scotia Biologics to develop proprietary CAR-T treatments for cancer and anti-viral indications. First CAR-T products will target solid tumours.

TC BioPharm Opens First Overseas Office in Japan

Located at the Kanagawa Prefecture (Greater Tokyo area), TC BioPharm will use the new office as a foundation to expand its cell therapy business through Japan and Asia.

14 February 2018

27 April 2018

TC BioPharm wins Life Sciences Company of the Year 2018

Awards celebrate transformational developments and discoveries made in Scotland.

TC BioPharm and the NIPRO Corporation Announce Strategic Collaboration

The NIPRO Corporation (TSE: 8086) and TC BioPharm announced today that they have formed a strategic collaboration to co-develop a novel immunotherapy product using TCB’s safe CAR-T platform, based on unique properties of modified gamma delta (γδ) T cells to selectively target cancer whilst leaving healthy cells untouched.

07 February 2018

08 December 2017

TC Biopharm Announces Strategic Collaboration with bluebird bio

bluebird bio, Inc. (Nasdaq: BLUE) and Scottish immunotherapy company TC BioPharm today announced a strategic collaboration and license agreement focused on gamma delta CAR T cells.

TC BioPharm Announces CAR-T Licensing Deal With UCL Business

UCL academics will assist TCB with development of treatment for leukemia. Clinical programme will see first patients treated in 2018.

06 Sep 2017

02 August 2017

TCB Selected For EU Horizon 2020 Funding to Progress Novel, Mass-Market Cell Therapies to Clinical Trial

€4million grant would allow Scottish company to develop next-generation cancer therapies for multiple tumour types

Funding represents the largest EU-award to any UK company for development of a healthcare therapeutic product

 

TCB wins ‘Entrepreneurial Business Leadership Award’

TC BioPharm won the ‘Entrepreneurial Business Leadership Award’ at the annual Scottish Life Sciences Dinner & Awards yesterday evening (2nd February, 2017).

02 February 2017

30 January 2017

Scottish immunotherapy company raises over £6m for innovative cancer treatments

TC BioPharm secures funding to progress lead product – ImmuniCell® to phase III clinical trial in patients with skin, lung and kidney cancer

TC BioPharm starts clinical study in cancer patients

Oncology centres in Glasgow and Edinburgh commence recruitment of skin, lung and kidney cancer patients Novel therapy ‘ImmuniCell®’ uses ‘killer cells’ to target the tumour Biotechnology company TC BioPharm Ltd (TCB) has today announced its MHRA-approved (Medicines and Healthcare Regulatory Agency) clinical study has commenced, treating patients suffering from several different tumour types including melanoma

16 December 2015

09 September 2015

TC BioPharm granted approval to treat cancer patients

Trials to Commence in October at the Beatson West of Scotland Cancer Centre in Glasgow Melanoma, Lung and Kidney Cancer Patients First to be Treated Biotechnology company TC BioPharm Ltd (TCB) has today announced it has been granted a Clinical Trial Authorisation (CTA) by UK regulators to treat cancer patients with its novel cell therapy

Investing Women appoint Director to TC BioPharm Board

Oil and Gas Entrepreneur Adds Business Experience To Cancer Treatment Firm Female angel investment group Investing Women has appointed oil and gas entrepreneur Lorraine Porter as non-executive director to the board of biotechnology company TC BioPharm.

31 August 2015

13 July 2015

TC BioPharm Ltd raises £1.2m to commence treatment of UK cancer patients

Biotechnology company TC BioPharm Ltd (TCB) announced today it has raised £1.18 million in equity and grant funding to treat UK-based patients with melanoma, lung and kidney cancer.

TC BioPharm gets green light for cancer trial

TC BioPharm (TCB) has been handed the right to become the only biotechnology company outside Japan to trial immunotherapy to treat patients with cancer.

07 January 2015

Search